Signal transducer and activator of transcription 3 (STAT3) protein has been linked to cardiovascular disease (CVD) through multiple pathways in experimental and animal studies. STAT3 gene variation was examined as a predictor of incident CVD in a subcohort of 529 incident white dialysis patients. Fifteen single-nucleotide polymorphisms of the STAT3 gene were genotyped. Haplotypes were estimated using software PHASE 2.1, and associations with first CVD event were tested using Cox proportional hazards analysis. Adjusted global tests of haplotype association with incident CVD and inflammation markers were performed using permutated P value in R-package Haplo.score. An a priori specified additive genetic model was assumed for haplotype analysis. Both genotypes (four single nucleotide polymorphisms with P < 0.001) and haplotypes (P ‫؍‬ 0.002 overall) were associated with incident CVD. Two major haplotype blocks, blocks A and C, were identified. Compared with common haplotype A-1, A-3 was associated with a hazard ratio (HR) of 0.70 (95% confidence interval [CI] 0.51 to 0.94) for CVD events after adjustment for covariates including C-reactive protein (CRP) and interleukin 6. Compared with common haplotype C-1, C-3 was associated with an adjusted HR of 2.12 (95% CI 1.25 to 3.57) for CVD events. Associations were independent of inflammation markers, but IL-6 levels were 14% lower (geometric mean ratio 0.86; 95% CI 0.77 to 0.96) per copy of haplotype A-3 compared with haplotype A-1 in block A after adjustment for CRP and other risk factors (P ‫؍‬ 0.008). Variation in the STAT3 gene is associated with the risk for CVD among white dialysis patients independent of serum IL-6 and CRP levels.
T he protein signal transducer and activator of transcription 3 (STAT3) can both activate and repress transcription level of many genes through the Janus kinasesignal transducer and activator of transcription pathways (1) . In particular, laboratory studies have suggested that STAT3 can affect cardiovascular disease (CVD) risk by modulating transcription of genes in several different pathways, leading to various cardiovascular intermediate phenotypes. STAT3 has been shown to be the most potent activator of acute-phase gene transcription among the family of STAT transcription factors (2) . It can either promote or inhibit inflammation through mediating effects of IL-6 or IL-10 (3-5), respectively. For example, STAT3 mediates IL-6 effects on angiotensinogen gene expression, which plays a critical role in cardiovascular homeostasis and has significant proinflammatory actions in the vascular wall (6, 7) . STAT3 knockout mice have been shown to have an increased production of proinflammatory cytokines (8) and increased fibrosis and susceptibility to inflammation-induced heart damage (9) . In addition, STAT3 affects endothelial function through effects on endothelial production of nitric oxide (10) , intercellular adhesion molecule-1 (11) , and chemokine (12) . STAT3 also has been shown to play protective roles in myocardial adaptation to stress, such as ischemia injury (13) (14) (15) . The beneficial action of late ischemic preconditioning on myocardial necrosis is mediated through STAT3 upregulation of the inducible nitric oxide synthase protein and cyclooxygenase (16, 17) .
Although experimental and animal studies support the role of STAT3 in CVD development, no human studies have exam-ined the association between STAT3 gene polymorphisms and CVD risk. Results from laboratory studies may not be generalizable to humans. Dialysis patients are subject to multiple proinflammatory stimuli, which can unmask underlying genetic susceptibilities. We therefore used data from the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study to examine whether polymorphisms of the STAT3 gene can predict CVD risk in white incident dialysis patients and whether any observed associations are independent of inflammation markers.
Materials and Methods

Study Design and Population
The CHOICE study is a multi-center, prospective study to investigate treatment choices and outcomes of dialysis care among patients who begin dialysis. Its rationale and design have been reported (18) . Briefly, the CHOICE study recruited 1041 incident dialysis patients from 81 Dialysis Clinic Inc. clinics between 1995 and 1998. Eligibility criteria for CHOICE study included ability to provide informed consent for participation, age older than 17 yr, and ability to speak English or Spanish. Patients were enrolled a median of 45 d from initiation of chronic dialysis (98% within 4 mo); 54% of the cohort had diabetes at baseline, and 51% of the cohort died by December 1, 2001 . Because of a limited sample size of black patients (n ϭ 246) in the CHOICE cohort for haplotype-based genetic analyses, our analysis is limited to white CHOICE study participants with DNA samples (n ϭ 529). All patients provided informed consent. The Johns Hopkins University School of Medicine Institutional Review Board and the review boards for the clinical centers approved the protocol.
Outcomes
The primary outcome was the first fatal or nonfatal atherosclerotic CVD event, including myocardial infarction, cerebrovascular accident, coronary artery bypass graft, percutaneous coronary angioplasty, peripheral artery bypass, nontraumatic amputation, abdominal aortic aneurysm repair, or carotid endarterectomy after initiation of dialysis. Multiple sources, including the Health Care Financing Administration, providers, and patient reports, were used to identify the potential events. Medical records were requested and reviewed preliminarily by a study nurse or a physician. An end point review committee adjudicated events on the basis of criteria that were developed specifically for the dialysis population. Because of a time lag in availability of administrative data, completed data for CVD events were available through November 1, 2000. Serum high-sensitive C-reactive protein (hsCRP) and IL-6 were measured at baseline using high-sensitivity ELISA with an intra-assay coefficient of variation 8.9% and ultrasensitive ELISA with an intra-assay coefficient of variation 7%, respectively.
Exposure Variables
Data on demographics and risk factors were collected by CHOICE study questionnaire at baseline. Major confounding variables included age; gender; smoking; baseline dialysis modality; body mass index; BP; history of diabetes, CVD, and congestive heart failure; serum albumin, total cholesterol, and HDL cholesterol. GFR at baseline was obtained from the Medicaid and Medicare Medical Evidence report. Dialysis modality at baseline was defined as the type of dialysis being used at 4 wk after enrollment in the study and was obtained from clinic records. Peritoneal dialysis included all forms (continuous ambulatory peritoneal dialysis, continuous cycling peritoneal dialysis, and intermittent cycling peritoneal dialysis). The Index of Coexistent Disease was calculated on the basis of assessment of medical records for physical impairment and coexisting disease severity. Scores on this index range from 0 (no comorbid condition) to 3 (highest severity of comorbid conditions). Baseline serum albumin, total cholesterol, and HDL cholesterol were assayed uniformly on all participants with standard methods using baseline specimen that was stored at Ϫ80°C.
Single-Nucleotide Polymorphism Selection and Genotyping Methods
Fifteen single-nucleotide polymorphisms (SNP) of the STAT3 gene were selected on the basis of the following criteria: (1) SNP were resequenced and validated by the National Heart, Lung, and Blood Institute Program for Genomic Applications; (2) each SNP had a minor allele frequency Ն5%; (3) the set of SNP covered major blocks in Europeans identified by HapMap; and (4) the ABI TaqMan assay (Applied Biosystems, Foster City, CA) was feasible. SNP were genotyped using the TaqMan system. Assay protocols are available upon request. Water samples were included as negative controls to assess potential cross-contamination between samples, and 47 blind replicates were used to estimate assay reproducibility.
To assess for potential population stratification, we genotyped a panel of 87 ancestry-informative SNP to measure admixture (19) . The degree of individual genetic admixture was estimated using a maximum-likelihood approach and characterized as percentage of European ancestry (PEA) (20) . PEA was categorized as a result of its highly skewed distribution among white individuals.
Statistical Analyses
Baseline characteristics between patients with incident CVD events and patients without CVD events were tested using t test or 2 tests as appropriate. Values of hsCRP and IL-6 were log transformed because of their skewed distributions. Allele and genotype frequencies for each SNP were computed and tested for departures from Hardy-Weinberg proportions. Both single SNP and haplotype analyses were performed. For each single SNP, either a dominant or a recessive model was nested within a co-dominant model, and the resulting likelihood ratio tests between nested models were used to identify the best genetic model. Haplotype block structure was identified among the 15 SNP according to linkage disequilibrium structure using the confidence interval (CI) method implemented in Haploview 3.2 (21) . Using a Bayesian method implemented in software PHASE 2.1 (22, 23) , each individual's haplotypes (diplotypes) were estimated using all 15 SNP for analysis of haplotypes across the entire gene or only the four SNP in block A and the five SNP in block C for block-specific analysis. Because of the uncertainty of estimated haplotype pairs from population data, PHASE 2.1 outputs several pairs of haplotype for each individual when there is an uncertainty. Each pair is assigned a posterior probability of certainty. The pair with the highest probability for an individual was called the "most likely pair" and was used (1) in Cox proportional hazard models to assess hazard ratios of first CVD event since dialysis for haplotypes and (2) in linear regression to examine haplotype associations with serum IL-6 and hsCRP levels. Linear regression models were conducted with log-transformed hsCRP or IL-6 as the dependent variable, and exponentiated coefficients were reported as ratios. Haplotypes with frequencies of Ͻ5% were combined. Left truncation technique was used in Cox proportional hazard models to account for the time lag between start of dialysis and time of study enrollment. Robust variance was used in each model to account for possible within-clinic correlations. An a priori specified additive genetic model was assumed for haplotype modeling.
To test the robustness of results from survival analysis using the most likely pair estimates of haplotype and to account for multiple comparison, we conducted linear regression models and logistic regression models for the association of haplotype with inflammation markers and CVD, respectively, using Haplo.glm in R package Haplo.stats (24, 25) . Adjusted global tests with permutation-derived P values implemented in Haplo.score also were conducted. Haplo.glm accounts for haplotype ambiguity by directly modeling an individual's phenotype as a function of each estimated haplotype pair weighted by their estimated probability.
Results
Baseline Characteristics, Minor Allele Frequency, and Haplotype Distribution
A total of 230 CVD cases occurred among 529 dialysis patients who were followed for 3 to 6 yr (median 2 yr). Table 1 presents the distributions of traditional and ESRD-related risk factors for CVD. As expected, participants with incident CVD after dialysis were more likely to be older and had greater prevalence of CVD, congestive heart failure, and diabetes. Furthermore, these individuals had significantly lower serum cholesterol and albumin levels but higher levels of the inflammation markers serum hsCRP and IL-6. Treatment modality did not differ between those with and without incident CVD. Almost all 529 self-reported white individuals in this study had at least 88% European ancestry according to the 87 ancestryinformative markers that were typed (median PEA ϭ 0.99; interquartile range 0.97 to 0.99). Markers of genetic admixture were not associated with CVD events.
A total of 15 SNP in STAT3, at an average spacing of 5.7 kb, were genotyped, including one synonymous coding SNP in the nearby STAT5 gene (6-kb away), two in the 3Ј-untranslated region, and 12 in introns. The kappa values of the 47 blind replicates ranged from 0.88 to 1.00 (mean 0.96; SD 0.03). All SNP were in Hardy-Weinberg equilibrium. Minor allele frequency and location of each SNP are reported in Table 2 . Three blocks were identified using the CI method; the second block consisted of two SNP (Figure 1 ). There was a high degree of linkage disequilibrium among the SNP. The mean pair-wise DЈ was 0.86. Haplotype frequencies from all 15 SNP as well as the first (block A) and the third (block C) blocks are shown by incident CVD status in Table 3 .
Single SNP, Inflammation Markers, and CVD Figure 2 shows P values of hazard ratios (HR) of CVD for each SNP after adjustment for other risk factors. Four SNP (rs1135669, rs8081431, rs9912773, and rs17880815) were significantly associated with incident CVD, each with P Ͻ 0.001. For 15 comparisons, the Bonferroni-corrected critical P value is 0.003. However, no significant associations were found between any single SNP and serum level of IL-6 and hsCRP.
Haplotype, Inflammation Markers, and CVD
Using all 15 SNP, six major haplotypes were estimated. Similar to single SNP results, haplotypic variations in STAT3 were significantly associated with CVD risk in this population. Table  3 shows a shortage of haplotype 3 among those with incident odds ratio (OR) of prevalent CVD was 1.32 (95% CI 0.65 to 2.65) for haplotype 3 and 0.93 (95% CI 0.46 to 1.86) for haplotype 6. To elucidate further the location of the association signal, we constructed haplotypes within blocks A and C. Whereas haplotype A-3 was less common among those who developed CVD events, haplotype C-3 was more common in those individuals (Table 3) . Table 4 summarizes results from multivariable Cox proportional hazards regression analyses by blocks. After adjustment for all haplotypes from both blocks as well as other risk factors, compared with common haplotype A-1, A-3 showed a significant protective effect on CVD (P ϭ 0.02). Compared with common haplotype C-1, C-3 showed a significant harmful effect on CVD (P ϭ 0.005). There were no significant interactions between STAT3 haplotypes and baseline diabetes or serum levels of IL-6 and CRP on CVD risk.
Median of the probability of the most likely pairs (diploid genotypes) estimated from PHASE 2.1 was 0.99 (interquartile range 0.89 to 1.00) for overall haplotypes and 1.00 (interquartile range 1.00 to 1.00) for both block A and block B haplotypes. The above Cox proportional hazard models were repeated using only haplotypes with a probability of 1, and the results were similar. All regression models were rerun adjusting for genetic admixture, and no significant changes were observed.
The association between STAT3 gene variation and CVD risk from Cox proportional models became somewhat stronger and more significant after adjustment. Detailed analysis suggested that this was not the result of a single confounder or influential outliers but was a combination of multiple variables, with baseline congestive heart failure being one of the more important. In addition, adjusting for baseline GFR did not change the observed associations. To test further the robustness of the survival analyses using estimated haplotypes, we estimated OR for CVD associated with each haplotype using a two-step iteration process that simultaneously imputes haplotypes and estimates their association with CVD implemented in Haplo.glm. The resulting OR were similar to their corresponding HR (Table  4) . Moreover, permutation-derived P values of global tests from Haplo.score were 0.02 for haplotypes from all 15 SNP, 0.02 for block A haplotypes, and 0.01 for block C haplotypes. These Figure 2 . P values of adjusted hazard ratios from Cox proportional model with single SNP. P values were obtained from the best genetic model; models were adjusted for age; gender; smoking; baseline dialysis modality; body mass index; systolic BP; comorbidity score; baseline diabetes, CVD, and congestive heart failure; and serum albumin, total cholesterol, HDL cholesterol, C-reactive protein, and IL-6 levels.
associations remained significant even after adjustment for inflammation markers (Table 4 , model 2). Associations from single SNP analyses were in the same direction as those from haplotype analyses. Compared with haplotypes 1 and A-1, haplotypes 3 and A-3 were associated with 8% lower (geometric mean ratio 0.92; 95% CI 0.79 to 1.06) and 14% lower (geometric mean ratio 0.86; 95% CI 0.77 to 0.96), respectively, IL-6 levels after adjustment for hsCRP and other covariates that were used in model 1 of Table  4 in a linear regression model that used the most likely pairs of haplotype for each patient. A linear model in Haplo.glm showed similar results. The HR for incident CVD was 1.22 (95% CI 1.11 to 1.34) per doubling of IL-6 and 1.24 (95% CI 1.14 to 1.35) per doubling of hsCRP level after adjustment for all haplotypes and other risk factors. These HR were similar to those obtained from models without adjustment for haplotypes. Variations in STAT3 were not associated with hsCRP levels. The observed association between inflammation markers and STAT3 gene variation remained after adjustment for baseline use of lipid-lowering medication and angiotensin-converting enzyme inhibitors.
Haplotype and Mortality
A total of 281 deaths occurred during 1427 person-yr of follow-up. Haplotype 6, consisting of A-2 and C-3, was the only haplotype that was significantly associated with all-cause mortality (HR 1.54; 95% CI 1.14 to 2.08; P ϭ 0.005).
Discussion
In our cohort, STAT3 gene variation was associated with CVD risk in white dialysis patients. Three major blocks were identified in 529 white dialysis patients. Compared with common haplotypes A-1 and C-1, respectively, block A haplotype A-3 marks decreased CVD risk and block C haplotype C-3 marks increased CVD risk. Furthermore, associations between STAT3 variation and CVD risk could not be explained by the association of STAT3 variation with serum IL-6 levels, suggesting alternative pathways through which STAT3 may influence CVD risk.
To our knowledge, this is the first study to examine the associations between STAT3 polymorphisms and CVD risk in humans. The rich information from the CHOICE study enabled us to examine the independent association between STAT3 gene variation and CVD risk adjusting for traditional and ESRD-related CVD risk factors. The use of incident dialysis patients minimized bias that is caused by the use of prevalent cases. All 15 SNP were genotyped and validated, and together they cover major haplotype blocks of the gene; therefore, these SNP adequately represent major haplotype variation in STAT3. We used a combination of single SNP and haplotype-based methods to investigate the association of variation in STAT3 with CVD risk.
Studies on animal or human tissues have shown several biologic pathways through which STAT3 affects CVD development. STAT3 has been shown to regulate both proinflammatory and anti-inflammatory processes through targeting the promoter regions of IL-6 and IL-10 genes (3-5), respectively. Negative feedback exists among STAT3, IL-6, and IL-10 through a family of inhibitor proteins that are referred to as suppressor of cytokine signaling (1). Our study showed that block A of the STAT3 gene is associated with IL-6 level. However, the association between the STAT3 gene and inflammatory markers may be affected by the anti-inflammatory effects of STAT3.
In addition to influencing CVD risk by regulating inflamma- a Model 1 was adjusted for all haplotypes; age; gender; smoking; baseline dialysis modality; BMI; SBP; comorbidity score; diabetes, baseline CVD, and congestive heart failure; and serum albumin, total cholesterol, HDL cholesterol. Model 2 was adjusted for model 1 plus IL-6 and CRP. For Cox regression models, haplotypes from both blocks were included; for logistic regression models, haplotypes from one block were included. CI, confidence interval; HR, hazard ratio; OR, odds ratio.
b P Ͻ 0.05. c P Ͻ 0.01.
tion, STAT3 may affect CVD risk through its action on vascular endothelial function (10 -12) , angiotensinogen gene expression (6, 7) , regulation of the inducible nitric oxide synthase protein and cyclooxygenase (16, 17) , and myocardial adaptation to stress (13) (14) (15) . Associations between STAT3 and CVD remained after adjustment for inflammatory markers, suggesting that STAT3 affects CVD risk through pathways other than inflammation. Because STAT3 protein cannot be measured except at the cellular level, we are unable to test whether the observed association is through transcription and expression of the STAT3 gene. However, many studies have shown in vitro that mutation of the STAT3 gene is associated with STAT3 transcription and expression. For example, mutations of the STAT3 promoter in murine myeloid leukemic cells were associated with STAT3 mRNA changes (26) . Study further suggested that minimal mutations in the murine STAT3 gene alone may alter dramatically the ratio of STAT3␣ to STAT3␤ mRNA in cells (27) . Murine cardiac myocytes that were transfected with wild-type or mutated-type STAT3 cDNA were associated with the amount of STAT3 protein (28) . A mutation of the STAT3 gene in human macrophages was associated with the amount of STAT3 protein (4) .
The findings that there was no or an opposite association between STAT3 haplotype and prevalent CVD may be due to survival bias in this cohort. For example, compared with haplotype 1, patients with haplotype 6 are at higher risk for CVD and therefore have higher risk for death. This would result in lower frequency of haplotype 6 among individuals who had prevalent CVD and survived to be included in our study, which would lead to an attenuated or even reversed association between haplotype 6 and prevalent CVD. However, in a prospective study of incident CVD, such as CHOICE, this survival bias would be minimized because we have captured all deaths as a result of CVD in our study. Our findings are unlikely due to population stratification, because adjusting for genetic admixture did not change our findings. The survival analysis did not take into account haplotype ambiguity, which can magnify statistical significance. However, the logistic regression implemented in Haplo.glm accounted for the haplotype ambiguity by weighting the probability of each haplotype, although it was not able to utilize fully the time-to-event data of CHOICE. Therefore, we performed both analyses and found consistent results. In addition, accounting for multiple comparisons in both single SNP analysis and the haplotype analysis did not alter the results.
Our study has several limitations. Because of the relatively small number of black CHOICE participants and the large number of haplotypes estimated in STAT3, our analysis was limited to only white CHOICE participants. Although allele frequencies of the 15 SNP were similar as reported by other sources, including HapMap, Perlegen, and National Heart, Lung, and Blood Institute Program for Genomic Applications, findings from this study require replication in other large cohorts, including other races. The observed associations may be due to unmeasured confounders. The lack of association between STAT3 gene variations and hsCRP levels may be the result of misclassification because of nongenetic influences. Serum hsCRP was measured only at one point, and this problem may be compounded by the high intraindividual variation of serum CRP in the dialysis population (29) . In addition, we did not investigate less common SNP in this gene (minor allele frequency Ͻ5%).
Conclusion
We provide evidence for association between STAT3 polymorphisms and serum IL-6 level and incident CVD risk in white dialysis patients. The associations between STAT3 and CVD were independent of inflammatory markers. These findings need replication and further characterization of the STAT3 gene to identify causal variation that may code for an alternative pathway, not mediated by inflammation, between STAT3 and CVD.
